<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2478">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363463</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2020-09</org_study_id>
    <nct_id>NCT04363463</nct_id>
  </id_info>
  <brief_title>Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress</brief_title>
  <acronym>PROVID-19</acronym>
  <official_title>Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SARS-Cov2 viral pandemic is responsible for a new infectious disease called COVID-19
      (CoronaVIrus Disease), is a major health problem. Respiratory complications occur in 15 to
      40%, the most serious is acute respiratory distress syndrome (ARDS).

      The management of COVID-19 is essentially symptomatic with respiratory oxygen supplementation
      in mild forms to invasive mechanical ventilation in the most severe forms.

      Prone position (PP) reduced mortality in patients with ARDS in intensive care. Ding et al
      showed that PP and high flow oxygenation reduced the intubation in patients with moderate to
      severe ARDS.

      The investigators hypothesize that the use of PP in spontaneously ventilation patients under
      oxygen standard could decrease incidence of intubation or non-invasive ventilation or death
      compared to conventional positioning management in medical departments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter randomized controlled study. 400 patients with COVID-19 documentation
      and undergoing oxygen therapy will be randomly assigned, with a 1:1 ratio, to conventional
      positioning or repeated prone sessions.

      The control group will have conventional positioning: semi-seated in bed or seated in a
      chair. The prone position is not allowed during the day (it is allowed at night if it is the
      natural sleeping position).

      The intervention group will have:

        -  Repeat sessions of 30 min to 1 hour of PP followed by 2 hours of conventional position.
           The goal is 5 sessions of prone position over the day between 7 am and 10 pm.

        -  The maximum of prone position at night. Patients must be able to take position by
           themselves or with minimal assistance. The rails will be positioned in order to prevent
           falling out of bed. The patient will be free to choose his preferred prone position as
           long as the back is not compressed
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled multicenter trial Ratio 1:1</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.</measure>
    <time_frame>Day 28</time_frame>
    <description>To show that PP in spontaneously ventilation patients could reduce the risk of acquiring the following event (composite endpoint):
Endotracheal intubation
Or non-invasive ventilation (NIV) with two pressure levels
And/or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration in days for the change of 2 points on the WHO ordinal scale</measure>
    <time_frame>Day 28</time_frame>
    <description>Show that the use of prone position improves the WHO ordinal scale score by 2 points faster (after randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate (%) of intubation and invasive ventilation in the 2 randomization groups.</measure>
    <time_frame>Day 28</time_frame>
    <description>Show that prone position with spontaneous ventilation reduces the need for endotracheal intubation and invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups</measure>
    <time_frame>Day 28</time_frame>
    <description>Show that prone position with spontaneous ventilation reduces the use of non-invasive ventilation at two pressure levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen therapy in the 2 randomization groups.</measure>
    <time_frame>Day 28</time_frame>
    <description>Show that prone position in spontaneous ventilation reduces the time under oxygen therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization in the 2 randomization groups.</measure>
    <time_frame>Day 28</time_frame>
    <description>Show that prone position reduces the length of hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality and mortality at D28 in the 2 randomization groups</measure>
    <time_frame>Day 28</time_frame>
    <description>Compare the hospital mortality of the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate (%) of need for transfer to intensive care unit</measure>
    <time_frame>Day 28</time_frame>
    <description>Compare the incidence of the need for resuscitation transfer between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days.</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the impact of the use of non-invasive ventilation and intubation on the entire hospital stay when the hospital stay is longer than 28 days between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID19</condition>
  <condition>Oxygen Therapy</condition>
  <condition>Prone Position</condition>
  <condition>Spontaneous Ventilation</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Conventional positioning</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional positioning : prone position</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 sessions (30 min to 1 hour) of prone position during the day (between 7 am to 10 pm) followed by 2 hours of conventional positioning (semi-seated in bed or seated in a chair)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prone position</intervention_name>
    <description>5 sessions (30 min to 1 hour) of prone position during the day (between 7 am to 10 pm) followed by 2 hours of conventional positioning (semi-seated in bed or seated in a chair)</description>
    <arm_group_label>Interventional positioning : prone position</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 18 to 85 years old

          -  With COVID-19 documentation

          -  Undergoing oxygen therapy (nasal cannula, medium or high concentration mask or high
             flow nasal oxygen therapy)

          -  Able to move to PP by him/herself or with minimal assistance

          -  Written consent

          -  Hospitalized in COVID medical department for less than 72 hours

        Exclusion Criteria:

          -  Pregnant (positive pregnancy test during screening) or breastfeeding women

          -  Patient on long-term oxygen therapy or Continuous Positive Airway Pressure (CPAP) or
             Non-Invasive Ventilation (NIV) at home

          -  Chronic Obstructive Pulmonary Disease (COPD) Patient stage 3 or 4

          -  Patient with known chronic diffuse interstitial lung disease

          -  Patient with neuromuscular pathology

          -  Contraindication to the PP (recent thoracic trauma, pneumothorax, orthopaedic fracture
             preventing mobilization, ...)

          -  Deep vein thrombosis of the lower limbs with effective anticoagulation for less than
             48 hours

          -  Hemodynamic instability (MAP &lt; 65 mm Hg) persisting for more than 1 hour

          -  Respiratory rate greater than 40 cycles per minute

          -  Excessive use of accessory respiratory muscles (as judged by the clinician)

          -  Indication for curative NIV (acute pulmonary edema or acute hypercapnic respiratory
             failure)

          -  Intestinal Occlusive Syndrome

          -  Patient unable to protect upper airway

          -  Inability to understand French or to follow instructions for the prone position.

          -  Person under guardianship

          -  Protected Majors

          -  Not affiliated to French social security

          -  Decision not to forgo life sustaining therapy

          -  Patient discharged from an intensive care unit and has been treated by invasive or
             non-invasive mechanical ventilation at 2 pressure levels during the resuscitation
             stay.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai-Anh NAY, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHR Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie POUGOUE TOUKO</last_name>
    <phone>+33238744086</phone>
    <email>elodie.pougoue-touko@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de DAX</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elsa NYAMANKOLLY, Dr</last_name>
      <email>nyamankollye@ch-dax.fr</email>
    </contact>
    <investigator>
      <last_name>Elsa NYAMANKOLLY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD de VENDEE</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marine MORIER, Dr</last_name>
      <email>marine.morrier@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>MARINE MORIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de LA ROCHELLE</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier POUGET-ABADIE, Dr</last_name>
      <email>xpougetabadie@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier POUGET-ABADIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans - Service Pneumologie</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvie DRUELLE, Dr</last_name>
      <email>sylvie.druelle@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie DRUELLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'Orleans - Service Maladies Infectieuses</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aymeric SEVE, Dr</last_name>
      <email>aymeric.seve@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Aymeric SEVE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-François GAUTIER, Pr</last_name>
      <email>jean-francois.gautier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François GAUTIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere - Medecine Interne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda LOPES, Dr</last_name>
      <email>amanda.lopes@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Amanda LOPES, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre SELLIER, Pr</last_name>
      <email>pierre.sellier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre SELLIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de PERPIGNAN - Service Maladies infectieuses</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Léa COLOMBAIN, Dr</last_name>
      <email>lea.colombain@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Léa COLOMBAIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan - pneumologie</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Léa COLOMBAIN, Dr</last_name>
      <email>lea.colombain@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Léa COLOMBAIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas BIZIEN, Dr</last_name>
      <email>n.bizien@ch-cornouaille.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas BIZIEN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Service Médecine interne et immunologie Clinique</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François MAILLOT, Pr</last_name>
      <email>francois.maillot@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>François MAILLOT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Service Pneumologie</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent PLANTIER, Pr</last_name>
      <email>laurent.plantier@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent PLANTIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU DE TOURS - Service Médecine interne et maladies infectieuses</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louis BERNARD, Pr</last_name>
      <email>l.bernard@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Louis BERNARD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020 Apr 21;323(15):1499-1500. doi: 10.1001/jama.2020.3633.</citation>
    <PMID>32159735</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.</citation>
    <PMID>32167524</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>Oxygen therapy</keyword>
  <keyword>Prone position</keyword>
  <keyword>Spontaneous ventilation</keyword>
  <keyword>Acute respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

